Supplementary 3: Upadacitinib outcomes

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Upadacitinib | | | | | | | | | | |
| Indication | Birth Outcomes | | | | | Congenital Malformation | Exposure Until | | | |
|  | Live Birth | Spontaneous Abortion | Still Birth | Ectopic Pregnancy | Elective Termination |  | First | Second | Third | Ongoing |
| RA | 18 | 13 | 0 | 0 | 3 | 0 | 34 | 0 | 0 | 0 |
|  | 52.9% | 38.2% | 0.0% | 0.0% | 8.8% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% |
| PsA | 4 | 1 | 0 | 1 | 0 | 0 | 6 | 0 | 0 | 0 |
|  | 66.7% | 16.7% | 0.0% | 16.7% | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% |
| spondyloarthritis | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
|  | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% |
| AD | 11 | 2 | 0 | 0 | 11 | 0 | 23 | 1 | 0 | 0 |
|  | 45.8% | 8.3% | 0.0% | 0.0% | 45.8% | 0.0% | 95.8% | 4.2% | 0.0% | 0.0% |
| UC | 6 | 1 | 0 | 0 | 3 | 0 | 10 | 0 | 0 | 0 |
|  | 60.0% | 10.0% | 0.0% | 0.0% | 30.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% |
| CD | 3 | 2 | 0 | 0 | 0 | 1 | 5 | 0 | 0 | 0 |
|  | 60.0% | 40.0% | 0.0% | 0.0% | 0.0% | 33.3% | 100.0% | 0.0% | 0.0% | 0.0% |
| NR | 22 | 18 | 0 | 1 | 7 | 0 | NR | NR | NR | NR |
|  | 45.8% | 37.5% | 0.0% | 2.1% | 14.6% | 0.0% | NR | NR | NR | NR |
| Total | 65 | 37 | 0 | 2 | 24 | 1 | 78 | 2 | 0 | 0 |
| 128 | 50.8% | 28.9% | 0.0% | 1.6% | 18.8% | 1.5% | 97.5% | 2.5% | 0.0% | 0.0% |